Telix Pharmaceuticals Limited

Contributing Author

Recent Articles by Telix Pharmaceuticals Limited

Oct-14	Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded TLX GlobeNewswire
Sep-23	CMS Grants Transitional Pass-Through Status for Gozellix TLX GlobeNewswire
Sep-09	Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis TLX GlobeNewswire
Aug-26	Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference TLX GlobeNewswire
Aug-20	Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth TLX GlobeNewswire
Jul-29	Telix H1 2025 Results: Investor Webcast Notification TLX GlobeNewswire
Jul-22	Telix Reports $204M Revenue, Up 63% YOY TLX GlobeNewswire
Jul-09	Gozellix Receives Permanent HCPCS Code TLX GlobeNewswire
Jun-23	Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT TLX GlobeNewswire
Jun-20	Telix Precision Medicine Announces AlFluor Radiochemistry Platform TLX GlobeNewswire
Jun-19	Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025 TLX GlobeNewswire
Jun-11	Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S. TLX GlobeNewswire
Jun-03	Telix Investor Day in New York City on June 11, 2025: Presenting KOLs TLX GlobeNewswire
May-22	Telix to Host Investor Day in New York City on June 11, 2025 TLX GlobeNewswire
May-07	Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy TLX GlobeNewswire